Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Abstract

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

1 - 12 . (canceled) 
     
     
         13 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the steps of:
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 500 mg nicotinic acid once per day and wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased.   
     
     
         14 . The method according to  claim 13 , wherein the hyperlipidemic is dosed at night or in the evening. 
     
     
         15 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the steps of:
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 750 mg nicotinic acid once per day and wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased.   
     
     
         16 . The method according to  claim 15 , wherein the hyperlipidemic is dosed at night or in the evening. 
     
     
         17 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the steps of:
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 1000 mg nicotinic acid once per day and wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased.   
     
     
         18 . The method according to  claim 17 , wherein the hyperlipidemic is dosed at night or in the evening. 
     
     
         19 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the steps of:
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 2000 mg nicotinic acid once per day and wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased.   
     
     
         20 . The method according to  claim 19 , wherein the hyperlipidemic is dosed at night or in the evening. 
     
     
         21 . The method according to  claim 13  or  14 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic after the ingestion of food by said hyperlipidemic or as said hyperlipidemic lies down to go to sleep. 
     
     
         22 . The method according to  claim 15  or  16 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic after the ingestion of food by said hyperlipidemic or as said hyperlipidemic lies down to go to sleep. 
     
     
         23 . The method according to  claim 17  or  18 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic after the ingestion of food by said hyperlipidemic or as said hyperlipidemic lies down to go to sleep. 
     
     
         24 . The method according to  claim 19  or  20 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic after the ingestion of food by said hyperlipidemic or as said hyperlipidemic lies down to go to sleep.